source
- RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo TherapeuticsRallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
- Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trialData presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…